A Phase 1/2 Dose Escalation and Expansion Study of Combination APL-501 or Nivolumab With APL-101 in Locally Advanced or Metastatic Hepatocellular and Renal Cell Carcinoma
Latest Information Update: 18 May 2022
At a glance
- Drugs Geptanolimab (Primary) ; Nivolumab (Primary) ; Vebreltinib (Primary)
- Indications Carcinoma; Liver cancer; Renal cell carcinoma
- Focus Adverse reactions
- Acronyms APOLLO-1
- Sponsors Apollomics
- 03 May 2022 Status changed from active, no longer recruiting to discontinued.
- 07 Jun 2021 Planned End Date changed from 15 Dec 2020 to 15 Dec 2021.
- 07 Jun 2021 Planned primary completion date changed from 15 Sep 2020 to 15 Sep 2021.